Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: jcmoore who wrote (880)	5/4/1999 10:22:00 AM
From: Beltropolis Boy	Respond to of 947

>Here is the real news!!!!!!!!!! thank YOU, jc! the fat has been officially cut! (i just knew there had to be more than that focus press release.) well, our patience is (finally) beginning to be rewarded. i see we hit $7 already. cheers, -chris.

To: jcmoore who wrote (880)	5/10/1999 8:49:00 PM
From: Beltropolis Boy	Respond to of 947

MISONIX BRINGS SUIT AGAINST FORMER LICENSEES FARMINGDALE, N.Y.--(BUSINESS WIRE)--May 10, 1999--Misonix, Inc. ("Misonix") (Nasdaq:MSON) announced that it had commenced an action in the United States District Court for the District of Nevada against Medical Device Alliance, Inc. and LySonix, Inc. As previously announced by Misonix, the defendants were in default as licensees under the license agreement covering its ultrasonic soft tissue aspirator, being marketed as the LySonix 2000. Misonix had terminated the license agreement in January, 1999. The suit seeks, among other things, damages for breach of contract, the recovery of the balance of the equipment held by the licensees, recovery of more than $2 million for sale of the products and royalties, and the restraint of the licensees from any further sales of the equipment.

To: jcmoore who wrote (880)	5/13/1999 8:55:00 AM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 947

Misonix Announces Third Quarter Results Business Wire - May 12, 1999 17:10 FARMINGDALE, N.Y.--(BUSINESS WIRE)--May 12, 1999--Misonix, Inc. (NASDAQ: MSON) today reported results for its fiscal 1999 third quarter and nine months ended March 31, 1999. Revenue for the nine-month period ending March 31, 1999 decreased 1% to $17.2 million, compared to $17.4 million for the same period in fiscal 1998. The results reflect a slight decrease in revenue from medical products due to a delay in orders received from our licensee, U.S. Surgical, as well as a reduction in shipments of Mystaire Division products due to concentrated efforts on shipments for the fourth quarter and beyond for two major orders. After reserving $2.1 million for possible bad debt, the company recorded a net profit of $751,000 or $.11 diluted earnings per share for the nine months ended March 31, 1999, compared to net income of $2,887,000 or $.43 diluted earnings per share for the same period in fiscal 1998. Without the effects of the bad debt reserve, the Company would have reported net income of $2,117,000, or $.32 diluted earnings per share for the nine months ended March 31, 1999. Revenue for the three-month period ended March 31, 1999 was $5.8 million compared to $6.5 million for the same period in fiscal 1998. The Company recorded net income of $566,000 for the quarter ended March 31, 1999, compared to $1,035,000 for the same period in fiscal 1998. The reserve for bad debt is against accounts receivable due from Medical Device Alliance, Inc. and its wholly owned subsidiary, LySonix, Inc. as licensees for the Misonix ultrasonic soft tissue aspirator. On May 7, 1999, the Company brought an action against the licensees seeking collection of indebtedness and enforcement of its security interest against the remaining portion of inventory. Michael A. McManus, Jr., President and Chief Executive Officer, stated: "We are very pleased with the continued growth in our core lines of business. We have to remember that our nine month revenue of $17.2 million did not include any revenue from the soft tissue aspirator, showed delays in orders from U.S. Surgical as they were completing their acquisition by Tyco, and reflected a reduction in shipments in the Mystaire division while it was working on two major orders for shipment in the fourth quarter. We also ended the quarter with a record backlog of $10 million. Our previously announced settlement with Mentor will allow us to return to the production and sale of the soft tissue aspirator with both our machine and Mentor's unit. Production could begin as soon as this fourth quarter. The liposuction business continues to be one of the fastest growing segments of the cosmetic surgery business and we are pleased to be back in it with Mentor. We will begin work in the near future on the development of the next generation of equipment for Focus Surgery. They will be paying us to develop with them a new machine for use on benign prostate tumors. Focus hopes to have the approval for use of this machine in the U.S. in mid 2000. Our recently announced agreement in principle with Hearing Innovations will, when finalized, not only enable us to utilize our expertise in ultrasound to add value in the production of their hearing products, but also to participate with them in the near future in the sale of their tinnitus product to the 12 million severe tinnitus sufferers in the United States. We expect that each of these developments will add to our continuing growth and income and result in increased value for our shareholders."

To: jcmoore who wrote (880)	10/18/1999 11:56:00 AM
From: Beltropolis Boy	Respond to of 947

Misonix and Hearing Innovations Sign Agreement October 18, 1999 11:03 AM FARMINGDALE, N.Y.--(BUSINESS WIRE)--Oct. 18, 1999--Misonix Incorporated (MSON) today outlined the completion of a previously announced agreement in principle with Hearing Innovations Incorporated whereby Misonox will invest $750,000 in exchange for a 7% equity stake in the company. Warrants to purchase additional shares that would bring Misonix' interest in the company to over 15% are also part of the agreement. With the exercise of these warrants, Misonix will have the right to produce the products for Hearing Innovations and create a joint venture to market and sell Hearing Innovations' ultrasonic tinnitus product. Arthur S. Przybyl, President and CEO of Hearing Innovations, said, "This agreement represents a very important milestone for Hearing Innovations. Misonix is the perfect partner to help us launch the HiSonic(R) into the marketplace, given its expertise in ultrasound technology and medical device sales. We anticipate the market launch of the HiSonic(R) through our Test Partners Program and have already signed up several clinical audiologists to dispense and market it." Michael A. McManus, Jr., President and CEO of Misonix, Inc. commented, "The Hearing Innovations' HiSonic(R) is a very exciting product. Anyone whose hearing is not improved by a hearing aid or is a candidate for a cochlear implant may benefit from the HiSonic(R). Not only will people be able to hear for the first time with this non-invasive device but Hearing Innovations is developing another product that may also treat tinnitus (ringing in the ear) from which 12 million people suffer in the U.S." "Strategic alliances such as these are an integral part of our strategy to grow our Company. With our significant capabilities in research and development, manufacturing and marketing, we intend to build Misonix into a leading ultrasound technology company."